financetom
Business
financetom
/
Business
/
Trilogy Laboratories Acquires YNS Cosmeceuticals, Bringing Pharmaceutical Expertise and Physician Leadership to a Trusted Skincare Brand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trilogy Laboratories Acquires YNS Cosmeceuticals, Bringing Pharmaceutical Expertise and Physician Leadership to a Trusted Skincare Brand
Jul 2, 2026 6:37 AM

The acquisition combines YNS's established skincare philosophy with Trilogy Laboratories' pharmaceutical formulation expertise, FDA-registered manufacturing capabilities, and physician leadership to guide the brand's next stage of growth.

FORT MYERS, Fla., July 2, 2026 /PRNewswire/ -- Trilogy Laboratories today announced the acquisition of YNS Cosmeceuticals, a trusted skincare brand known for its simple, effective approach to healthy skin. The acquisition brings new pharmaceutical formulation expertise, physician leadership, and advanced manufacturing resources to the brand while preserving the products and philosophy that have earned YNS a loyal customer following.

Rather than introducing another skincare line into an already crowded marketplace, Trilogy chose to acquire YNS because it recognized a brand built around an idea that aligns closely with its own philosophy: effective skincare should be straightforward, thoughtfully formulated, and easy to maintain.

For years, YNS has focused on a streamlined skincare system anchored by its signature Power Trio: Cell-Tight, Infusion O2, and Radiance. Instead of encouraging consumers to build increasingly complicated routines, the brand has emphasized consistency, quality formulations, and products designed to work together as part of a simple daily regimen.

The acquisition marks an important milestone for YNS by combining that established approach with Trilogy Laboratories' pharmaceutical formulation expertise and physician leadership to guide the brand's future growth.

Leading that effort is Dr. Kristen Flaharty, Chief Executive Officer of Trilogy Laboratories. A pharmaceutical scientist with experience in prescription drug development, formulation science, and product commercialization, Dr. Flaharty applies pharmaceutical development principles, including ingredient science, delivery system optimization, quality systems, and product evaluation, to the development of advanced skincare products.

She is joined by Dr. Patrick Flaharty, a board-certified physician and dual fellowship-trained facial cosmetic surgeon whose decades of clinical experience treating facial aging and skin health provide valuable insight into future product development and innovation.

Together, their complementary expertise strengthens the future direction of YNS while remaining true to the qualities that have earned the brand a loyal following.

Supporting that vision is Trilogy Laboratories' extensive manufacturing infrastructure. The company operates an FDA-registered cosmetic manufacturing facility where skincare products are developed and manufactured under rigorous quality standards. Trilogy provides formulation development, manufacturing, quality assurance, regulatory oversight, and product innovation for physician practices, medical spas, and skincare brands throughout the United States.

For existing YNS customers, the acquisition is intended to provide continuity rather than change. The current product collection remains the foundation of the brand, and Trilogy's immediate priority is preserving the integrity, consistency, and quality of the formulations customers already trust.

Looking ahead, Trilogy plans to invest thoughtfully in the continued growth of YNS through expanded educational resources, ongoing research and development, an enhanced digital experience, and carefully considered product innovation. Any future additions to the product line will complement the brand's existing philosophy of simple, effective skincare rather than create unnecessary complexity.

"We acquired YNS because it already represented many of the qualities we value most—thoughtful formulations, a clear philosophy, and the trust of its customers," said Dr. Kristen Flaharty, Chief Executive Officer of Trilogy Laboratories. "Our responsibility is to preserve that foundation while supporting the brand's future with pharmaceutical formulation expertise, physician leadership, and continued innovation."

The acquisition represents the beginning of a long-term investment in YNS, combining the brand's established philosophy with Trilogy Laboratories' pharmaceutical expertise and physician leadership to thoughtfully guide its next generation of skincare innovation.

More About Trilogy Laboratories

Trilogy Laboratories is an FDA-registered cosmetic manufacturer based in Fort Myers, Florida, founded by pharmaceutical scientist Dr. Kristen Flaharty. The company develops and manufactures premium skincare products for brands, physician practices, and medical spas, combining pharmaceutical formulation expertise with rigorous quality systems, testing, and product development. Trilogy is led by Dr. Kristen Flaharty, Chief Executive Officer, and draws on the clinical expertise of Dr. Patrick Flaharty, a board-certified physician and dual fellowship-trained facial cosmetic surgeon.

More About YNS Cosmeceuticals

YNS Cosmeceuticals is a skincare brand built on the belief that effective skincare does not require a complicated routine. Best known for its signature Power Trio: Cell-Tight, Infusion O2, and Radiance, the brand has earned a loyal customer following by emphasizing quality formulations, consistency, and a straightforward approach to daily skincare. Under Trilogy Laboratories' ownership, YNS will continue building on that foundation while benefiting from expanded pharmaceutical formulation expertise, physician leadership, and continued product innovation.

Media Contact

Trilogy Laboratories / YNS Cosmeceuticals

Dr. Kristen Flaharty

(239) 939-5454

www.ynsskincare.com

trilogylaboratories.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trilogy-laboratories-acquires-yns-cosmeceuticals-bringing-pharmaceutical-expertise-and-physician-leadership-to-a-trusted-skincare-brand-302816199.html

SOURCE Trilogy Laboratories

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pan American Silver Completes $245 Million Sale of La Arena to Zijin Mining Group Unit
Pan American Silver Completes $245 Million Sale of La Arena to Zijin Mining Group Unit
Dec 3, 2024
06:24 AM EST, 12/03/2024 (MT Newswires) -- Pan American Silver ( PAAS ) said Tuesday that it has completed the sale of its La Arena unit to Zijin Mining Group's Jinteng (Singapore) Mining unit for $245 million in cash. The unit owns the La Arena gold mine and the La Arena II project in Peru, Pan American said. Pan American...
Pan American Silver Sells La Arena Gold Mine and La Arena II Project in Peru for US$245 Million and Royalties
Pan American Silver Sells La Arena Gold Mine and La Arena II Project in Peru for US$245 Million and Royalties
Dec 3, 2024
06:26 AM EST, 12/03/2024 (MT Newswires) -- Pan American Silver ( PAAS ) on Tuesday said it completed the sale of a 100% stake in La Arena S.A., which owns the La Arena gold mine and the La Arena II project in Peru. The buyer, Zijin Mining Group subsidiary Jinteng (Singapore) Mining, paid US$245 million in cash and granted Pan...
US Steel Takeover by Nippon Steel Faces Potential Opposition From Trump
US Steel Takeover by Nippon Steel Faces Potential Opposition From Trump
Dec 3, 2024
06:24 AM EST, 12/03/2024 (MT Newswires) -- United States Steel's ( X ) proposed takeover by Japan's Nippon Steel will be opposed by President-elect Donald Trump once he takes office, Trump said in a Truth Social post. I will block this deal from happening. Buyer Beware!!! Trump wrote on Monday, further adding that he will introduce a series of tax...
BlackRock to buy HPS Investment for $12 bln in major private credit push
BlackRock to buy HPS Investment for $12 bln in major private credit push
Dec 3, 2024
Dec 3 (Reuters) - BlackRock ( BLK ) will buy private credit firm HPS Investment Partners for about $12 billion in an all-stock deal, the companies said on Tuesday, as the world's largest asset manager seeks to expand in a red-hot market. Private credit, or lending to companies by institutions other than banks, has grown rapidly in recent years as...
Copyright 2023-2026 - www.financetom.com All Rights Reserved